1.90
-4.04%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genoway
Its shares trade on Euronext Paris under the ticker ALGEN.PA. It has been listed since 4 May 2007. In the fiscal year to 31 December 2025, it reported revenue of €21.0m and net income of €928,000. At that date it held total assets of €45.4m and shareholders' equity of €25.0m.
genOway SA engages in the development of genetically-modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2007-05-04. The firm offers a range of services, comprising site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). In addition, genOway SA's clients have access to its validated tool and consultancy services from a dedicated project manager. The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage. The company has also formed partnerships with Charles River Laboratories, Altana Pharma, Dainihon Sumitomo Pharmceuticals and Euratools, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 May 2007
- Employees
- 113
- Website
- genoway.com ↗
Leadership
Pay as last reported
- Dr. Alexandre FraichardChief Executive Officer, since 1999
- Mr. Benjamin BruneauFinancial and Administrative Director
- Mr. Christian GrenierChairman of the Board, since 2014
- Mr. Laurent FraisseDirector
- Mr. Robert LeonDirector - Representative of Finoway, since 2012
- Mr. Andre TartarDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genoway SA has a strong reputation in the biotechnology industry.
- The company has a talented and experienced team of researchers and scientists.
- Genoway SA offers a wide range of genetically engineered models and services.
- The company has a robust intellectual property portfolio.
- Genoway SA has a global presence and serves clients in multiple countries.
Weaknesses
- The company heavily relies on a few key clients, making it vulnerable to client-specific risks.
- Genoway SA has higher production costs compared to some competitors.
- The company may face regulatory challenges in certain markets.
- Genoway SA's product and service offerings may be affected by rapid technological advancements.
Opportunities
- The increasing demand for genetically modified organisms (GMOs) presents an opportunity for Genoway SA to expand its market share.
- Collaboration with pharmaceutical and biotechnology companies can lead to new product development opportunities.
- Genoway SA can leverage its expertise to enter new geographical markets.
- The company can explore partnerships with academic institutions and research organizations.
Threats
- Intense competition from established players and emerging startups can pose a threat to Genoway SA's market position.
- Increased regulations and potential ethical concerns regarding GMOs can impact the company's operations.
- Economic downturns or fluctuations can lead to a decrease in customer spending on biotechnology services.
- Technological advancements by competitors may outpace Genoway SA's innovations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.